DOCSLIB.ORG

The Distribution and Excretion of Phenobarbital

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Distribution and Excretion of Phenobarbital The Distribution and Excretion of Phenobarbital William J. Waddell, Thomas C. Butler J Clin Invest. 1957;36(8):1217-1226. https://doi.org/10.1172/JCI103518. Research Article Find the latest version: https://jci.me/103518/pdf THE DISTRIBUTION AND EXCRETION OF PHENOBARBITALI By WILLIAM J. WADDELL2 AND THOMAS C. BUTLER (From the Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, N. C.) (Submitted for publication February 25, 1957; accepted April 4, 1957) The 5,5-disubstituted barbituric acids used tion of pK' for the pH value of 7.4. The function medicinally are weak acids with ionization ex- is without a maximum. It is greater the lower ponents in a range such that their dissociation is the value of pK'. influenced by physiological changes of pH. There The pK' of phenobarbital at 370 C. and ionic is much evidence that cellular membranes in gen- strength of 0.16 (approximately the ionic strength eral are permeable to the undissociated forms of of the inorganic ions of plasma) is 7.2. Owing to weak acids and impermeable to the ionized forms the strong electron-attracting force of the phenyl (1). The experiments of Clowes, KeItch, and group in phenobarbital, this drug is a considerably Krahl (2) are interpreted as indicating that a stronger acid than the commonly used barbituric number of barbituric acid derivatives penetrate acid derivatives having only alkyl or alkenyl groups Arbacia eggs only as the undissociated molecules. in the 5-position. The drugs of the latter types The influence of urinary pH on the renal excretion for the most part have pK' values under the same of weak acids has been explained in terms of tubu- conditions in the range of 7.6 to 8.0 (5) .8 lar permeability to the undissociated species and N-methylated barbituric acid derivatives, such as impermeability to the ionic species (3, 4). hexobarbital, mephobarbital, and metharbital, have Changes in the concentration of the undissociated pK' values about 0.4 unit higher than the corre- form of a weakly acidic drug accompanying physi- sponding non-methylated compounds (6). Thio- ological changes in the pH of blood or urine can barbituric acid derivatives are stronger acids than have important effects on the distribution, excre- the analogous oxygen compounds. Thiopental has tion, and pharmacological actions of the drug. a pK' value of 7.3 at 370 C. and ionic strength of The rate of change of the concentration of un- 0.16.' Thus phenobarbital has a lower pK' value dissociated acid with pH is maximal when the pK' than any other commonly used barbituric acid of the acid equals the pH. However, of greater derivative. It is evident from Figure 1 that the interest is the proportion by which the concentra- proportional change in the concentration of undis- tion of undissociated acid changes with a change sociated form resulting from a small change in pH of pH, i.e., the rate at which the concentration of at pH 7.4 is much greater for phenobarbital than undissociated form is changing divided by that for other hypnotic barbituric acids with pK' values concentration. This function is expressed by the of 7.6 to 8.0. For instance, it is 1.8 times as. great following equation, as for barbital or amobarbital, which have pK' val- ues of 7.7. d (HA) 1 Because of the important influence that physio- d(pH) - log. 10 1OP logical shifts in pH might be expected to have on (HA) 1OpH + 10pK"1 the distribution and excretion of phenobarbital, an in which (HA) is the concentration of undissoci- 8By spectrophotometry and by potentiometric titra- ated acid. In Figure 1 is shown the proportional tion we have found higher values of pK' for several rate of change of the concentration of the undis- barbituric acid derivatives at 25° C. than did Krahl and sociated form of a weak acid with pH as a func- also lower temperature coefficients. Our directly meas- ured values at 370 C. and ionic strength of 0.16 are about I This investigation was supported in part by a re- 0.2 unit higher than the values calculated from Krahl's search grant (B-384) from the National Institute of data. Neurological Diseases and Blindness, National Institutes 4This value was determined spectrophotometrically and of Health, Public Health Service. by potentiometric titration. The value of 8.2 reported by 2Public Health Service Research Fellow of the Na- Brodie et al. (7) was obtained by titration in ethanol- tional Institute of Neurological Diseases and Blindness. water solution. 1217 1218 WILLIAM J. WADDELL AND THOMAS C. BUTLER residue was taken up in the 1 M phosphate buffer of pH 8 used in the original method (8), and the subsequent -2.0 steps of that method carried out as usual. When the specificity of this method was investigated by the pro- cedure described by Butler, Mahaffee, and Waddell (8), v -1.5- the ether/buffer partition coefficients were found to con- form closely to the values expected for phenobarbital. The methods used for the determination of phenobarbi- x v-0. tal in dog and human urine when applied to urine free of drug gave calculated values that did not exceed 5 per cent of the phenobarbital concentrations that were to be 0.5- experimentally measured in urine. The various drugs that were administered to dogs did not interfere with the determination of phenobarbital in plasma or urine. Weighed samples of 1 to 5 Gm. of tissues were ho- 10o 62 64 " i0 i72 74 f. I0 SI 14 mogenized with weighed 5-ml. portions of 1 M phos- pK phate buffer of pH 8. The homogenizer was a device FIG. 1. THE PROPORTIONAL RATE OF CHANGE OF THE consisting of sharp blades mounted on a shaft driven at CONCENTRATION OF THE UNDISsocIATED FoRM OF A WEAK high speed by an electric motor. A 2-ml. sample of the ACD WITH PH AT PH 7.4 AS IT Is RELATED TO THE PK' homogenate was weighed, 1 ml. of the buffer of pH 8 OF THE AcID was added, and the subsequent steps of the analytical pro- The dotted line is the asymptote approached by the cedure were carried out in the same way as previously function as pK' decreases. described for plasma (8). When this method was ap- plied to tissues free of drug, the calculated phenobarbital investigation has been made of these effects. It concentrations did not exceed 1 #g. per Gm. Recovery of added to tissues was complete. was anticipated that the information to be gained phenobarbital Because higher concentrations of phenobarbital were might be of value in the treatment of phenobarbital found in liver than in other tissues, the specificity of the poisoning. An investigation has also been made method as applied to liver was investigated. A homoge- of other factors influencing the renal excretion of nate of a liver sample from a dog that had received phenobarbital. phenobarbital was extracted with ether in the same man- ner as used in the first extraction step of the regular METHODS analytical procedure. The ether extract was evaporated and the residue distributed between ether and 1 M phos- Determination of phenobarbital. For dog and human phate buffer of pH 8.2 in a 30-cell countercurrent distri- plasma and for dog urine the method of Butler, Mahaffee, bution train of the type described by Craig, Hausmann, and Waddell (8) was used. By measurements of parti- Ahrens, and Harfenist (10). Twenty-two effluent frac- tion coefficients between ether and buffers, the specificity tions of ether were withdrawn from the train. Frac- of this method for plasma had previously been demon- tions 11 to 22, which would contain p-hydroxy pheno- strated. By the same procedure it has been shown to barbital. if any were present, were analyzed for that have adequate specificity when applied to the determina- compound by the method described by Butler (9). No evi- tion of phenobarbital in dog urine. This method deter- dence was found of the presence of any p-hydroxy pheno- mines bound as well as unbound phenobarbital in plasma. barbital. Fractions 1 to 10 were combined and evaporated Human urine, unlike dog urine, contains unconjugated and the residue was put through the countercurrent dis- p-hydroxy phenobarbital (9), which interferes with the tribution train, the light solvent being a mixture of 30 per determination of phenobarbital. The interfering meta- cent (v/v) ether and 70 per cent 2,2,4-trimethylpentane bolic product was separated by partitioning between ben- and the heavy solvent a 1 M phosphate buffer of pH 7.2. zene and water. To 1 ml. of urine in a glass stoppered Thirty effluent fractions of light solvent were collected. tube was added 1 ml. of 1 N HCl and 12 ml. of benzene. These were individually extracted with 4-ml. portions of The tube was shaken and centrifuged. The aqueous phase the buffer of pH 11 used in the regular analytical pro- was then transferred by pipette to a second tube, where cedure. Each buffer extract was washed with 2 ml. of it was shaken with a fresh 12-ml. portion of benzene. purified ether and the phenobarbital concentration calcu- After centrifugation, the aqueous phase was removed and lated from the difference between the absorbency of the discarded. The first benzene extract was shaken with buffer at 240 m/ and that at 260 my. In Fractions 11 to 1 ml. of 0.1 N HCI. After centrifugation, the aqueous 30 the amounts of phenobarbital measured in this way con- phase was transferred to the second benzene extract.
Load more

Recommended publications
  • The Use of Barbital Compounds in Producing Analgesia and Amnesia in Labor
    University of Nebraska Medical Center DigitalCommons@UNMC MD Theses Special Collections 5-1-1939 The Use of barbital compounds in producing analgesia and amnesia in labor Stuart K. Bush University of Nebraska Medical Center This manuscript is historical in nature and may not reflect current medical research and practice. Search PubMed for current research. Follow this and additional works at: https://digitalcommons.unmc.edu/mdtheses Part of the Medical Education Commons Recommended Citation Bush, Stuart K., "The Use of barbital compounds in producing analgesia and amnesia in labor" (1939). MD Theses. 730. https://digitalcommons.unmc.edu/mdtheses/730 This Thesis is brought to you for free and open access by the Special Collections at DigitalCommons@UNMC. It has been accepted for inclusion in MD Theses by an authorized administrator of DigitalCommons@UNMC. For more information, please contact [email protected]. THE USE OF THE BARBITAL COMPOUl~DS IN PRODUCING ANALGESIA AND .AMNESIA.IN LABOR Stuart K. Bush Senior Thesis Presented to the College of Medicine, University of Nebraska, Omaha, 1939 481021 THE USE OF THE BARBITAL COMPOUNDS IN PROLUCING ANALGESIA AND AMNESIA IN LABOR The Lord God said unto Eve, "I will greatly mul­ tiply thy sorrow and thJ conception; in sorrow thou shalt bring forth children." Genesis 3:lti Many a God-fearing man has held this to mean that any attempt to ease the suffering of the child­ bearing mother would be a direct violation of the Lord's decree. Even though the interpretation of this phrase has formed a great barrier to the advance­ ment of the practice of relieving labor pains, attempts to achieve this beneficent goal have been made at va­ rious times throughout the ages.
    [Show full text]
  • Comparative Enhancing Effects of Phenobarbital, Amobarbital
    [CANCER RESEARCH 35,2884 2890, October 1975] Comparative Enhancing Effects of Phenobarbital, Amobarbital, Diphenylhydantoin, and Dichlorodiphenyltrichloroethane on 2-Acetylaminofluorene-induced Hepatic Tumorigenesis in the Rat Carl Peraino, R. J. Michael Fry, Everett Staffeldt, and John P. Christopher 2 Division of Biological and Medical Research, Argonne National Laboratory, Argonne, Illinois 60439 SUMMARY INTRODUCTION Earlier studies showed that phenobarbital feeding en- In earlier studies (27, 29), the prolonged feeding of hanced hepatic tumorigenesis in rats previously fed 2- phenobarbital to rats that had previously been fed AAF 3 for acetylaminofluorene for a brief period. As part of an a brief period markedly increased the subsequent incidence investigation of the mechanism of this enhancement, the of liver tumors. Using this sequential feeding regime, the present study evaluated the relative enhancing abilities of present study evaluated the relative tumorigenic enhancing amobarbital, diphenylhydantoin, and dichlorodiphenyltri- abilities of other compounds that, to varying degrees, chloroethane (DDT), agents that resemble phenobarbital to resemble phenobarbital in their effects on liver structure and varying degrees in their effects on liver structure and metabolism. The substances examined were amobarbital, metabolism. A comparison of hepatic tumor yields in rats diphenylhydantoin, and DDT. Table 1 compares relevant fed 2-acetylaminofluorene, followed by the test substance characteristics of these agents with those of phenobarbital, (sequential treatment), showed that amobarbital and di- reviewed previously (27, 29). Amobarbital is closest to phenylhydantoin had no enhancing activity, whereas the phenobarbital in structure and, like phenobarbital, alters enhancing effect of DDT was similar to that of phenobarbi- the metabolism of other drugs by the liver. Diphenylhydan- tal.
    [Show full text]
  • 89 Abstract Biological Activity and Analytical
    BIOLOGICAL ACTIVITY AND ANALYTICAL CHARACTERIZATION OF BARBITURIC ACID Vijaya Laxmi S, Janardhan B, Rajitha B ijcrr Vol 04 issue 07 Department of Chemistry, National Institute of Technology, Warangal Category: Review Received on:12/12/11 E-mail of Corresponding Author: [email protected] Revised on:15/01/12 Accepted on:28/02/12 ABSTRACT Earlier literature reports imply that this scaffold is having activity on central nervous system. According to the present studies it has become an attractive target for the development of drugs, which hold variety of biological activities. Derivatives of barbituric acid have attracted the attention of researchers in synthetic organic chemistry, as well as medicinal chemistry, for a long time as a result of their exceptionally diverse biological activity. Present review highlights the importance of the barbituric acid in the present context. ____________________________________________________________________________________ Keywords: Barbituric acid, Biological activity, biological activities that stand apart from Spectral studies, X-ray Crystallography, Dye previous medical utilization of barbituric acid properties. derivatives.4 However it is a precursor to barbituric acid derivatives widely been used in 1 INTRODUCTION the manufacturing of plastics,5 textiles,6 Barbituric acid (BA) is documented as the parent polymers,7 and pharmaceuticals,8-9 dental compound of the barbiturate drugs. (Fig.1). It is materials,10 water thinned or oil-based inks,11 used in the production of riboflavin, Nembutal, and as polymerization catalysts.12 In view of the and Phenobarbital.1-2 This class of compounds above observations it is worthwhile to make a has been extensively used in medical and brief review on it.
    [Show full text]
  • The Design and Synthesis of Novel Barbiturates of Pharmaceutical Interest
    University of New Orleans ScholarWorks@UNO University of New Orleans Theses and Dissertations Dissertations and Theses 5-21-2004 The Design and Synthesis of Novel Barbiturates of Pharmaceutical Interest Donna Neumann University of New Orleans Follow this and additional works at: https://scholarworks.uno.edu/td Recommended Citation Neumann, Donna, "The Design and Synthesis of Novel Barbiturates of Pharmaceutical Interest" (2004). University of New Orleans Theses and Dissertations. 1040. https://scholarworks.uno.edu/td/1040 This Dissertation is protected by copyright and/or related rights. It has been brought to you by ScholarWorks@UNO with permission from the rights-holder(s). You are free to use this Dissertation in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in University of New Orleans Theses and Dissertations by an authorized administrator of ScholarWorks@UNO. For more information, please contact [email protected]. THE DESIGN AND SYNTHESIS OF NOVEL BARBITURATES OF PHARMACEUTICAL INTEREST A Dissertation Submitted to the Graduate Faculty of the University of New Orleans in partial fulfillment of the requirements for the degree of Doctor of Philosophy in The Department of Chemistry by Donna M. Neumann B. A. University of New Orleans, 2000 May 2004 Dedicated to: My daughter, Madeline Megan Jenkins ii ACKNOWLEDGEMENTS I would like to express my utmost gratitude to my advisor, Professor Branko S.
    [Show full text]
  • Wo 2009/074533 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date PCT 18 June 2009 (18.06.2009) WO 2009/074533 A2 (51) International Patent Classification: (74) Common Representative: CIBA HOLDING INC.; C09B 67/14 (2006.01) C09B 57/04 (2006.01) Patent Department,, Klybeckstrasse 141, CH-4057 Basel C09B 67/20 (2006.01) C08K 5/00 (2006.01) (CH). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/EP2008/06701 1 kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, 8 December 2008 (08.12.2008) CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, (25) Filing Language: English EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (26) Publication Language: English LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, (30) Priority Data: MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, 07122749.0 10 December 2007 (10.12.2007) EP RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, 08157426.1 2 June 2008 (02.06.2008) EP TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (71) Applicant (for all designated States except US): CIBA ZW HOLDING INC. [CWCH]; Klybeckstrasse 141, CH-4057 (84) Designated States (unless otherwise indicated, for every Basel (CH).
    [Show full text]
  • Barbiturates for the Treatment of Alcohol Withdrawal Syndrome: ☆ a Systematic Review of Clinical Trials
    Journal of Critical Care 32 (2016) 101–107 Contents lists available at ScienceDirect Journal of Critical Care journal homepage: www.jccjournal.org Barbiturates for the treatment of alcohol withdrawal syndrome: ☆ A systematic review of clinical trials Yoonsun Mo, MS, Pharm.D., BCPS, BCCCP a,b,⁎, Michael C. Thomas, Pharm.D., BCPS, FCCP a,1, George E. Karras Jr., MD, FCCM b,2 a Department of Pharmacy Practice, Western New England University College of Pharmacy, 1215 Wilbraham Road, Springfield, MA 01119 b Mercy Medical Center, 271 Carew Street, Springfield, MA 01104 article info abstract Keywords: Purpose: To perform a systematic review of the clinical trials concerning the use of barbiturates for the treatment Barbiturates of acute alcohol withdrawal syndrome (AWS). Phenobarbital Materials and Methods: A literature search of MEDLINE, EMBASE, and the Cochrane Library, together with a man- Benzodiazepines ual citation review was conducted. We selected English-language clinical trials (controlled and observational Alcohol withdrawal syndrome studies) evaluating the efficacy and safety of barbiturates compared with benzodiazepine (BZD) therapy for Delirium tremens Systematic review the treatment of AWS in the acute care setting. Data extracted from the included trials were duration of delirium, number of seizures, length of intensive care unit and hospital stay, cumulated doses of barbiturates and BZDs, and respiratory or cardiac complications. Results: Seven studies consisting of 4 prospective controlled and 3 retrospective trials were identified. Results from all the included studies suggest that barbiturates alone or in combination with BZDs are at least as effective as BZDs in the treatment of AWS. Furthermore, barbiturates appear to have acceptable tolerability and safety pro- files, which were similar to those of BZDs in patients with AWS.
    [Show full text]
  • Original Article Effects of Repeated High Dosage of Chloral Hydrate and Pentobarbital Sodium Anesthesia on Hepatocellular System in Rats
    Int J Clin Exp Med 2015;8(7):10568-10576 www.ijcem.com /ISSN:1940-5901/IJCEM0008402 Original Article Effects of repeated high dosage of chloral hydrate and pentobarbital sodium anesthesia on hepatocellular system in rats Jianhong Yu1*, Xuehui Sun2*, Guifeng Sang3 1Department of Anesthesiology, Yuhuangding Hospital, Yantai 264000, China; 2Department of Rheumatology, Yuhuangding Hospital, Yantai 264000, China; 3Operating Room, Yuhuangding Hospital, Yantai 264000, China. *Equal contributors. Received March 24, 2015; Accepted July 2, 2015; Epub July 15, 2015; Published July 30, 2015 Abstract: This study aims to investigate the possible effects of repeated high dosage of chloral hydrate and pen- tobarbital sodium anesthesia on hepatocellular system in rats. Thirty Sprague Dawley rats were randomly divided into 3 groups: control group (group A), chloral hydrate group (group B) and pentobarbital sodium group (group C). Antioxidant enzymes superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), glutathione s transferase (GST) and catalase (CAT) activities and thiobarbituric acid-reactive substances (TBARS) level as well as serum biochemi- cal parameters alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and total bilirubin (T-BIL) were determined. Liver histopathological examinations were performed at termination. Furthermore, Bax and Bcl-2 expression, and caspase-3 activity were also evaluated. The SOD, GSH-Px, GST and CAT activities significantly decreased but TBARS levels increased in group B and C compared with group A. Hepatic injury was evidenced by a significant increase in serum ALT, AST and ALP activities in group B and C, which also con- firmed by the histopathological alterations. Moreover, administration of chloral hydrate and pentobarbital sodium could induce certain hepatic apoptosis accompanied by the upregulated Bax expression, the downregulated Bcl-2 expression and Bcl-2/Bax ratio, and the increase of caspase-3 activity.
    [Show full text]
  • Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: an American Academy of Sleep Medicine Clinical Practice Guideline Michael J
    pii: jc-00382-16 http://dx.doi.org/10.5664/jcsm.6470 SPECIAL ARTICLES Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline Michael J. Sateia, MD1; Daniel J. Buysse, MD2; Andrew D. Krystal, MD, MS3; David N. Neubauer, MD4; Jonathan L. Heald, MA5 1Geisel School of Medicine at Dartmouth, Hanover, NH; 2University of Pittsburgh School of Medicine, Pittsburgh, PA; 3University of California, San Francisco, San Francisco, CA; 4Johns Hopkins University School of Medicine, Baltimore, MD; 5American Academy of Sleep Medicine, Darien, IL Introduction: The purpose of this guideline is to establish clinical practice recommendations for the pharmacologic treatment of chronic insomnia in adults, when such treatment is clinically indicated. Unlike previous meta-analyses, which focused on broad classes of drugs, this guideline focuses on individual drugs commonly used to treat insomnia. It includes drugs that are FDA-approved for the treatment of insomnia, as well as several drugs commonly used to treat insomnia without an FDA indication for this condition. This guideline should be used in conjunction with other AASM guidelines on the evaluation and treatment of chronic insomnia in adults. Methods: The American Academy of Sleep Medicine commissioned a task force of four experts in sleep medicine. A systematic review was conducted to identify randomized controlled trials, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process was used to assess the evidence. The task force developed recommendations and assigned strengths based on the quality of evidence, the balance of benefits and harms, and patient values and preferences.
    [Show full text]
  • Article on Relative Abuse Liability of Triazolam
    Neuroscience & giobehaviora[Reviews. Vol. 9, pp. 133-151. 19_5. e Ankho International Inc. Printed in the U.S.A 0149-7634/85 5300 ÷ 00 Relative Abuse Liability of Triazolam: Experimental Assessment in Animals and Humans ROLAND R. GRIFFITHS,** RICHARD J. LAMB,* NANCY A. ATOR,* JOHN D. ROACHE* AND JOSEPH V. BRADY** Departments of *Psychiatry and tNeuroscience. The Johns Hopkins University School of Medicine 720 Rutland Avenue, Baltimore, MD 21205 GRIFFITHS, R. R., R. J. LAMB, N. A. ATOR, J. D. ROACHE AND J. V. BRADY. Relative abuse liability oftriazolam: Experimental assessment in animals and humans. NEUROSCI BIOBEHAV REV 9(1) 133--151. 1985.--The abuse liability of a drug is a positive, interactive function of the reinforcing and adverse effects of the drug. The relative abuse liability of the hypnotic henzodiazepine, triazoiam, has been controversial. This paper reviews animal and human studies beating on its relative abuse liability, including data on pharmacological profile, reinforcing effects, liking, speed of onset, discrimina- tive stimulus effects, subjective effects, physiological dependence, rebound and early morning insomnia, drug produced anxiety, lethality in overdose, psychomotor impairment, interactions with ethanol anterogr_e amnesia, impaired aware- ness of drug effect, and other psychiatric and behavioral disturbances. It is concluded that the abuse liability of triazolam is less than that of the intermediate duration barbiturates such as pentobarbital. Although there are considerable data indicating similarities of triazolam to other benzodiazepines, there is also substantial speculation among clinical inves- til_tors and some limited data suggesting that the abuse liability of triazolam is greater than that of a variety of other benzodiazepines, and virtually no credible data or speculation that it is less.
    [Show full text]
  • Management of Drug and Alcohol Withdrawal
    The new england journal of medicine review article current concepts Management of Drug and Alcohol Withdrawal Thomas R. Kosten, M.D., and Patrick G. O’Connor, M.D., M.P.H. From the Departments of Psychiatry (T.R.K.) ach year in the united states, approximately 8.2 million persons and Medicine (P.G.O.), Yale University are dependent on alcohol and 3.5 million are dependent on illicit drugs, includ- School of Medicine, New Haven, Conn.; e 1 and Veterans Affairs Connecticut Health- ing stimulants (1 million) and heroin (750,000). In a sample from primary care care System, West Haven, Conn. (T.R.K.). practice, 15 percent of patients had either an “at-risk” pattern of alcohol use or an alco- Address reprint requests to Dr. Kosten at hol-related health problem, and 5 percent had a history of illicit-drug use.2 With rates of Veterans Affairs Connecticut Healthcare System, Psychiatry 151D, 950 Campbell substance use so high, all patients should be carefully screened with validated instru- Ave., Bldg. 35, West Haven, CT 06516, or ments such as the CAGE questionnaire for alcohol dependence, which consists of the at [email protected]. following questions: Can you cut down on your drinking? Are you annoyed when asked N Engl J Med 2003;348:1786-95. to stop drinking? Do you feel guilty about your drinking? Do you need an eye-opener Copyright © 2003 Massachusetts Medical Society. drink when you get up in the morning? Physicians should be prepared to treat patients who have withdrawal syndromes.3 A carefully taken history should include the time of last use for each substance involved, and toxicologic screening should be performed to identify any additional substances used.
    [Show full text]
  • Repeated Zolpidem Treatment Effects on Sedative Tolerance, Withdrawal, Mrna Levels, and Protein Expression Brittany T
    University of Tennessee Health Science Center UTHSC Digital Commons Theses and Dissertations (ETD) College of Graduate Health Sciences 8-2016 Repeated Zolpidem Treatment Effects on Sedative Tolerance, Withdrawal, mRNA Levels, and Protein Expression Brittany T. Wright University of Tennessee Health Science Center Follow this and additional works at: https://dc.uthsc.edu/dissertations Part of the Medicinal and Pharmaceutical Chemistry Commons, and the Neurosciences Commons Recommended Citation Wright, Brittany T. (http://orcid.org/0000-0002-1501-6596), "Repeated Zolpidem Treatment Effects on Sedative Tolerance, Withdrawal, mRNA Levels, and Protein Expression" (2016). Theses and Dissertations (ETD). Paper 406. http://dx.doi.org/10.21007/ etd.cghs.2016.0408. This Dissertation is brought to you for free and open access by the College of Graduate Health Sciences at UTHSC Digital Commons. It has been accepted for inclusion in Theses and Dissertations (ETD) by an authorized administrator of UTHSC Digital Commons. For more information, please contact [email protected]. Repeated Zolpidem Treatment Effects on Sedative Tolerance, Withdrawal, mRNA Levels, and Protein Expression Document Type Dissertation Degree Name Doctor of Philosophy (PhD) Program Biomedical Sciences Track Neuroscience Research Advisor Scott A. Heldt, Ph.D. Committee Kristin M. Hamre, Ph.D. Michael P. McDonald, Ph.D. Kazuko Sakata, Ph.D. Jeffery D. Steketee, Ph.D. ORCID http://orcid.org/0000-0002-1501-6596 DOI 10.21007/etd.cghs.2016.0408 This dissertation is available at UTHSC Digital Commons: https://dc.uthsc.edu/dissertations/406 Repeated Zolpidem Treatment Effects on Sedative Tolerance, Withdrawal, mRNA Levels, and Protein Expression A Dissertation Presented for The Graduate Studies Council The University of Tennessee Health Science Center In Partial Fulfillment Of the Requirements for the Degree Doctor of Philosophy From The University of Tennessee By Brittany T.
    [Show full text]
  • Associated Neuronal Injury
    BRIEF COMMUNICATION Phenobarbital and Midazolam (i.p.) at P6, and the next day SE was induced with subcutane- ous (s.c.) pilocarpine hydrochloride (320mg/kg) together with Increase Neonatal Seizure- scopolamine methyl chloride (1mg/kg, i.p.) to block the periph- eral effect of pilocarpine. All experiments were conducted with Associated Neuronal Injury the approval of and in accordance with the regulations of the Institutional Animal Care and Use Committee of West Los Angeles VA Medical Center, and in accordance with the U.S. Daniel, Torolira, BS,1 1 Public Health Service’s Policy on Humane Care and Use of Lucie, Suchomelova, PhD, Laboratory Animals. 1,2,3 Claude G., Wasterlain, MD, and In preliminary experiments, we found that high doses of 1,2 Jerome, Niquet, PhD midazolam (6mg/kg, but not 3mg/kg) and phenobarbital (25mg/kg, but not 10mg/kg) induce apoptosis in control Status epilepticus is common in neonates and infants, (no-seizure) pups. Ten minutes after the development of stage 3 and is associated with neuronal injury and adverse seizures, some pups were treated with midazolam (3mg/kg, i.p., developmental outcomes. c-Aminobutyric acidergic SE1Mz group, n 5 36) and others with phenobarbital (10mg/ (GABAergic) drugs, the standard treatment for neona- kg, i.p., SE1Ph group, n 5 26). Some pups (SE group, tal seizures, can have excitatory effects in the neonatal brain, which may worsen the seizures and their effects. n 5 30) were kept untreated as SE controls and only received Using a recently developed model of status epilepticus saline (i.p.), whereas other pups receiving only midazolam in postnatal day 7 rat pups that results in widespread (3mg/kg, i.p., Mz group, n 5 6) or phenobarbital (10mg/kg, neuronal injury, we found that the GABAA agonists i.p., Ph group, n 5 8) were kept as no-seizure controls for phenobarbital and midazolam significantly increased injury comparison.
    [Show full text]